Navigation Links
deCODE Receives Nasdaq Deficiency Notice
Date:12/30/2009

REYKJAVIK, Iceland, December 30 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it has received a notice from the Nasdaq Stock Market ("Nasdaq") stating that for 30 consecutive business days the market value of the publicly held shares of its common stock has been below $15 million, the minimum level required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(3)(C). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), deCODE will be provided a period of 90 calendar days from the date of the notice in which to regain compliance. If at any time during this period the market value of the publicly held shares of deCODE's common stock is $15 million or more for a minimum of 10 consecutive business days, Nasdaq will provide deCODE with written confirmation of compliance and the matter will be closed.

As previously reported, deCODE has appealed the potential suspension of trading in its common stock and the subsequent delisting from Nasdaq pursuant to a notice from Nasdaq received on November 18, 2009. A decision on this matter is expected in January, 2010.

About deCODE

deCODE is a global leader in analysing and understanding the human genome. deCODE has identified key variations in the sequence of the genome conferring increased risk of major public health challenges from cardiovascular disease to cancer, and employs its gene discovery engine to develop DNA-based tests to assess individual risk of common diseases; to license its tests and intellectual property to partners; and to provide comprehensive, leading- edge contract services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme(TM), deCODE enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. Visit us on the web at http://www.decode.com; at http://www.decodediagnostics.com; at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding deCODE's expectations concerning the bankruptcy process and the continuation of day-to-day operations. deCODE's actual results could differ materially from those anticipated in the forward-looking statements as a result of risks and uncertainties, including, without limitation, (1) the impact of the announcement of its bankruptcy filing on deCODE's operations; (2) the ability of deCODE to maintain sufficient debtor-in-possession financing to fund its operations and the expenses of the Chapter 11 proceeding; (3) the ability of deCODE to obtain court approval of its motions in the Chapter 11 proceeding; (4) the outcome and timing of the proposed sale of deCODE's assets, including deCODE's ability to close a transaction with SagaInvestments, LLC or any other purchaser; (5) the uncertainty associated with motions by third parties in the bankruptcy proceeding; (6) deCODE's ability to obtain and maintain normal terms with vendors and service providers and contracts that are critical to its operation; (7) the effect of a potential delisting of our common stock from The Nasdaq Global Market; and (8) other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:

    deCODE genetics
    Joy Bessenger
    +1-212-481-3891
    ir@decode.is

    Edward Farmer
    +354-570-2819
    info@decode.is

    Gisli Arnason
    +354-570-1900
    info@decode.is


SOURCE DeCODE Genetics Inc


'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists Decode HIV Genome
2. BioTech Firm Decodes Current Swine Flu BioMarkers
3. deCODEme(TM) Takes on Heart Disease in February
4. Presentations at AHA expand on clinical utility of deCODEs DNA-based tests
5. deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business
6. deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer
7. Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
8. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
10. Masimo Rainbow SET(R) SpHb(TM) Measurement Receives New CPT Code and Medicare Pricing
11. Lexi-Comp, Inc. Receives Weatherhead 100 Honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Students interested in video can get a jump start on ... earn a $1,000 scholarship and have his or her video posted on the GenCure ... May 31, with the winner announced on June 9. , The competition is designed ...
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... For ... serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity ... (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, is ...
(Date:1/19/2017)... ... 2017 , ... For the second consecutive year, all five ... have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, Dr. Joshua ... by their peers for the 2017 list based on their exceptional patient care ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
(Date:1/18/2017)... 2017 Research and Markets has announced the addition ... User - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... Vital signs ... to reach $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring devices ...
Breaking Medicine Technology: